Sichenzia Ross Friedman Ference LLP Advises Laidlaw & Company on $10 million Secondary Public Offering of Cyclacel Pharmaceuticals, Inc.
NEW YORK, April 8, 2014 (GLOBE NEWSWIRE) — New York- based securities law firm, Sichenzia Ross Friedman Ference LLP announced that it has represented Laidlaw & Company (UK) Ltd. as sole underwriter in a $10 million secondary public offering for Cyclacel Pharmaceuticals, Inc. (“CYCC.” NASDAQ). The underwriting was pursuant to a prospectus supplement to an effective S-3 registration statement. The offering consisted of 2,857,143 shares of common stock at an offering price of $3.50 per share. The Sichenzia Ross Friedman Ference LLP team was led by partners Richard Friedman and Stephen Cohen.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Sichenzia Ross Ference LLP代表Quest Solutions，Inc。进行500万美元私募 - April 10, 2019
- Sichenzia Ross Ference LLP代表New Age Beverages Corp.与东西岸的2500万美元信贷工具 - April 2, 2019
- Sichenzia Ross Ference LLP宣布其2019年对ThinkEquity 会议进行白金级赞助 - March 29, 2019